Ultrahypofractionation and Simultaneous Integrated Boost in Breast Cancer: Early Side Effects Analysis.

作者：M. Dzhugashvili, Ana Serradilla, Jaume Fernández-Ibiza, G. García, Kirill Matskov Malinochka, L. Torres, Antonio Seral, J. Begara, D. Gonsalves, J. D. L. C. Troca, P. Poortmans, F. Couñago, Escarlata López · 发表于：International Journal of Radiation Oncology, Biology, Physics · 年份：2025 · DOI：10.1016/j.ijrobp.2025.02.003 · 被引用次数：9 · 研究领域：Medicine

PURPOSE The FAST-Forward study paved the way for ultrahypofractionation (UHF) in breast cancer. We prospectively registered and analyzed our case series receiving UHF + simultaneous integrated boost (SIB) to further reduce the treatment to a total of 5 days. The study aimed to present the 6-month early side effects results of the first patients treated with this scheme in 16 radiation oncology centers in Spain. METHODS AND MATERIALS A total of 242 breast cancer patients received adjuvant radiation therapy between April and December 2020. The median age was 61 years (interquartile range, 53-70). All patients underwent breast-conserving surgery. Chemotherapy (QT) was administered to 27.7%, and endocrine therapy to 85.1%. A SIB of 29 Gy was applied to 60.7% of the patients, while 39.3% did not have a boost indication. Breast radiation therapy (RT) with SIB to the tumor bed and regional node irradiation was done in 5.4 % of patients. RESULTS Most patients were treated with Volumetric modulated arc therapy (66.1%) and intensity modulated RT (30.6%). One patient received treatment by 3-dimensional techniques (0.4%) and 7 patients (2.9%) a combined intensity modulated RT-3-dimensional technique. Deep inspiration breath-hold was used in 16.9% of cases. At the end of treatment, erythema grade (G) 0 was presented in 56.1%, G1 in 43.1%, and G2 in 0.8%. G1 edema was observed in 14.6% and less than 1% had G2. After 6 months, 97% had G0 erythema, 3% G1, and 0% G2, while G1 edema was ob...